Clinical trials: Allergy to House Dust Mites
Asthma
House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma
The purpose of this trial is to investigate if treatment with house dust mite allergen immunotherapy tablet can reduce the risk of asthma exacerbation in subjects with house dust mite induced asthma.
- Trial name
- MITRA (NCT01433523)
- Testing
- ALK HDM AIT 6 DU, ALK HDM AIT 12 DU
- Where
- Germany
- Volunteers
- 834 people
- Sponsor
- ALK-Abelló A/S
Severe Asthma, Allergy to House Dust Mites
Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab
The aim of this drug trial is to evaluate the annualized asthma exacerbation rate under treatment with Acarizax versus placebo. The trial is intended for adults aged 18 to 65 with severe uncontrolled asthma and a house dust mite…
- Trial name
- TEZEPAIT (NCT07013123)
- Testing
- Tezepelumab, Acarizax
- Volunteers
- 38 people
- Sponsor
- University Hospital, Montpellier
House Dust Mite Allergy
Role of the Central Nervous System in Allergic Rhinitis
In order to evaluate the effects a nasal provocation on the activation of different brain regions, the investigators want to set up a clinical trial investigating the short-term effects of a nasal histamine provocation in healthy…
- Trial name
- NCT01777464
- Testing
- histamine
- Where
- Belgium
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Asthma
Mechanical Heat Recovery Ventilation on House Dust Mite Sensitive Asthma
Asthma has become increasingly common in the UK, demanding our consideration of the cause. Many patients with asthma are allergic to house dust mites, which thrive in modern housing.
- Trial name
- NCT00148096
- Testing
- Mechanical Heat Recovery Ventilation
- Where
- United Kingdom
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- University of Glasgow
Allergy to House Dust Mite
Validation of an Environmental Exposure Chamber for Inhalation Studies With House Dust Mite Allergen in Patients With Allergic Rhinitis
This clinical validation study is aimed at testing the efficacy of a new environmental challenge chamber (ECC) to induce symptoms of allergic rhinitis in patients allergic to house dust mite.
- Trial name
- NCT01275456
- Testing
- Exposure to house dust mite
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Fraunhofer-Institute of Toxicology and Experimental Medicine
Hypersensitivity
Vestibular Versus Sublingual Route of AIT Tablets
To evaluate the tolerability of the vestibular administration route of birch pollen, grass pollen, ragweed pollen, and house dust mite (HDM) AIT tablets compared with the sublingual route in adult subjects with allergic…
- Trial name
- NCT05119751
- Testing
- tree 12 SQ-Bet, GRASS 2800 BAU, RAGWEED 12 AMB A 1-U
- Where
- Canada
- Volunteers
- 172 people
- Sponsor
- Clinique Spécialisée en Allergies de la Capitale
Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae
Noninterventional Study on Tolerability and Safety of One Strength Updosing With Novo-Helisen Depot House Dust Mites
The goal of this non-interventional study is to investigate the safety and tolerability of a new simplified up-dosing schedule for Novo-Helisen Depot.
- Conditions
- Allergic Rhinitis Due to House Dust Mite, Allergic Conjunctivitis Due to Dermatophagoides Farinae, Allergic Conjunctivitis Due to Dermatophagoides Pteronyssinus, Allergic Asthma Due to Dermatophagoides Farinae
- Trial name
- NOVUS-UP (NCT07096440)
- Volunteers
- 105 people
- Sponsor
- Allergopharma GmbH & Co. KG
Mite Allergy, Rhinitis, Allergic
Comparative Evaluation of Safety and Immune Activity of New Immunotherapeutic Agents for HDM Allergic Rhinitis Patients
When administering clinical trial drugs to patients with house dust mite allergic rhinitis, safety/tolerance is comparatively evaluated as the primary outcome, and symptom improvement and immune activity of the disease are…
- Conditions
- Mite Allergy, Rhinitis, Allergic, House Dust Mite Rhinitis
- Trial name
- NCT05525650
- Testing
- House Dust Mite Extract, Dermatophagoides Farinae
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- RAPHAS
Perennial Allergy to House Dust Mite and/or Cat
Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
The purpose of the study is to test the efficacy of a vaccine against house dust mite and/or cat allergy compared to placebo in adult patients.
- Trial name
- NCT00575003
- Testing
- CYT003-QbG10
- Where
- 7 sites in Estonia, Latvia and 1 more
- Volunteers
- 64 people
- Sponsor
- Cytos Biotechnology AG
Allergic Rhinitis, Allergic Asthma
Clinical Trial to Evaluate the Efficacy and Safety of Polymerized, Mannan-Conjugated Dermatophagoides Allergen Extract
Prospective, randomised, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of polymerized and mannan conjugated allergen extract of Dermatophagoides for the treatment of allergic…
- Conditions
- Allergic Rhinitis, Allergic Asthma, Allergic Rhinoconjunctivitis, Allergy to House Dust Mite
- Trial name
- MM09-SLIM (NCT05641272)
- Testing
- 3,000 MM09, 9,000 MM09
- Where
- Argentina
- Volunteers
- 90 people
- Sponsor
- Inmunotek S.L.
Asthma
Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)
Prolongation of the EPAAC™ trial - NCT00152464 (The Early Prevention of Asthma in Atopic Children). 36 months study to evaluate the efficacy and safety of levocetirizine (LCTZ) in preventing the onset of asthma in young atopic…
- Trial name
- NCT00160563
- Testing
- LEVOCETIRIZINE
- Where
- 51 sites in Australia, Belgium and 8 more
- Volunteers
- 207 people
- Sponsor
- UCB Pharma
Pollen Allergy, Venom Allergy
Identification of B Regulatory Cells by Flow Cytometry
The goal of this laboratory and observational study is to develop a test to quantify B-regulatory cells in blood. This will be used to detect changes in B-regulatory cell populations in pollen and insect venom allergic patients…
- Trial name
- NCT06876506
- Testing
- Venepuncture, Allergen Specific Immunotherapy
- Where
- United Kingdom
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hull University Teaching Hospitals NHS Trust
Perennial Allergic Rhinoconjunctivitis, Allergic Asthma
Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy
The purpose of the study is to test the safety, tolerability, immunogenicity and clinical efficacy of the combination treatment AllQbG10 in patients with rhino-conjunctivitis and asthma due to house dust mite allergy in a…
- Trial name
- NCT00652223
- Testing
- CYT005-AllQbG10
- Where
- Switzerland
- Volunteers
- 21 people
- Sponsor
- Cytos Biotechnology AG
Allergic Rhinoconjunctivitis
A Research Study in Chinese People With Allergy to House Dust Mites, Using an Environmental Exposure Chamber
This trial evaluates the efficacy and safety of HDM SLIT-tablet in treatment of HDM AR. The efficacy is evaluated using an environmental exposure chamber (EEC).
- Trial name
- QUEST (NCT04176185)
- Testing
- Sublingual allergy immunological tablet
- Where
- 2 sites in Austria, China
- Volunteers
- 80 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinitis, House Dust Mite Allergy
AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)
Comparative analysis of the efficacy of intranasal MP29-02 (a novel formulation of azelastine and FP) has already been conducted in patients with moderate-to-severe seasonal AR.
- Trial name
- NCT02238353
- Testing
- azelastine + fluticasone
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
House Dust Mite Allergy
Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients
hdmASIT+TM product is based on highly purified allergen fragments from house dust mites. The purpose of this study is to assess the safety and clinical tolerability of subcutaneous immunotherapy with hdmASIT+TM in patients with…
- Trial name
- NCT03094845
- Testing
- hdmASIT+TM
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- ASIT Biotech S.A.
Allergy Testing, Peanut Allergies
BÜHLMANN BAT (Basophil Activation Test) in Allergy Diagnosis (Exploratory Pilot Study)
The goal of this exploratory pilot study is to generate early data needed for future validation studies of the automated BÜHLMANN BAT (Basophil activation test) assay.
- Conditions
- Allergy Testing, Peanut Allergies, Venom Allergy, House Dust Mite Allergy
- Trial name
- NCT07596303
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Bühlmann Laboratories AG
House Dust Mite Allergy
SUBLIVAC FIX Mite Mixture Dose Tolerability Study
Allergic rhinitis/rhinoconjunctivitis is a symptomatic disorder of the nose induced by an immunoglobulin E (IgE) mediated inflammatory response. Treatment may involve pharmacotherapy and specific immunotherapy (IT).
- Trial name
- DTS (NCT02345278)
- Testing
- SUBLIVAC FIX Mite mixture
- Where
- 10 sites in Germany
- Volunteers
- 81 people
- Sponsor
- HAL Allergy
Perennial Allergic Rhinitis, Rhinitis, Allergic
Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers
Alleviation of allergic symptoms induced by house dust mites when using the medical device AM-301. This clinical investigation explored the efficacy and safety of AM-301 when used to reduce symptoms of house dust mite sufferers.
- Trial name
- NCT05122143
- Testing
- Treatment A, Treatment B, Treatment C
- Where
- Canada
- Volunteers
- 37 people
- Sponsor
- Altamira Medica Ltd.
Allergic Rhinitis
Safety and Efficacy Study of Sublingual Immunotherapy (SLIT) to Treat House Dust Mite Allergic Rhinitis
The purpose of this study is to assess the efficacy of two doses of sublingual immunotherapy (SLIT) administered as allergen-based tablets once daily over a period of 12 months compared to placebo, for reduction of allergic…
- Trial name
- NCT00674700
- Testing
- 300 IR house dust mites allergen extract tablet, 500 IR house dust mites allergen extract tablet
- Volunteers
- 509 people
- Sponsor
- Stallergenes Greer